Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.49 |
| ▸ | MMP14 | P50281 | 3/20 | 0.49 |
| ▸ | PTPN22 | Q9Y2R2 | 5/20 | 0.48 |
| ▸ | MMP13 | P45452 | 5/20 | 0.46 |
| ▸ | MMP7 | P09237 | 2/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.46 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509267 | 0.93 | BCAT1 (0.50) | MMP2MMP14BCAT1 | |
| SCHEMBL6510457 | 0.87 | BCAT1 (0.46) | MMP2PTPN22MMP13BCAT1 | |
| SCHEMBL6509584 | 0.81 | MEN1 (0.48) | MMP2MMP14MMP13BCAT1 | |
| SCHEMBL6509898 | 0.77 | HDAC1 (0.61) | MMP2MMP14MMP13MMP7MMP1 | |
| SCHEMBL6509960 | 0.74 | PTPN22 (0.58) | PTPN22PTPN1PTPN12 | |
| SCHEMBL6510137 | 0.72 | MEN1 (0.60) | — | |
| SCHEMBL6514424 | 0.71 | ALDH1A1 (0.66) | — | |
| SCHEMBL6506293 | 0.71 | HDAC1 (0.58) | — | |
| SCHEMBL6506633 | 0.70 | RAB9A (0.74) | — | |
| SCHEMBL6507290 | 0.70 | HDAC1 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | claimed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137234-A1 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC11 | MMP2 305/4885MMP14 486/4885PTPN22 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.